Although selective ALK inhibitors represent an emerging strategy to treat ALK+ neoplasms including NPM‐ALK+ T‐cell lymphoma (Mosse et al., 2013), several resistance mechanisms to these inhibitors have been already identified and characterized, which represents an important limitation (Dong et al., 2016; Isozaki et al., 2016; Katayama et al., 2016; Zdzalik et al., 2014). The gene discussed is ALK; the disease is neoplasm.